N-nitrosamine risk assessment in pharmaceuticals: Where are we from a regulatory point of view in 2025?
N-nitrosamines have been a concern for decades due to their potential mutagenicity and widespread occurrence across various matrices. While evidence suggests carcinogenicity in animals, their potential carcinogenicity in humans has prompted their initial inclusion in the “cohort of concern” since in...
Saved in:
Main Authors: | Yue Zhang, Joëlle Widart, Eric Ziemons, Philippe Hubert, Cédric Hubert |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-12-01
|
Series: | Journal of Pharmaceutical and Biomedical Analysis Open |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2949771X25000350 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
N-nitrosamine Impurities in Medicines: Toxicity, Formation Pathways, Methods of Determination, and Limits (Review)
by: P. P. Shchetinin, et al.
Published: (2020-11-01) -
Green and sustainable LC-APCI-MS/MS method for simultaneous quantification of genotoxic nitrosamines in antidiabetic medication: sitagliptin
by: Sriram Pepakayala, et al.
Published: (2025-05-01) -
Scientific Justification and Policy Recommendations to the US Food and Drug Administration for Waiving Comparative Efficacy Studies
by: Sarfaraz K. Niazi
Published: (2025-05-01) -
ANALYSIS OF INTERNATIONAL REQUIREMENTS FOR DESIGNING OF CLINICAL TRIALS
by: O. S. Kobyakova, et al.
Published: (2019-01-01) -
Survey of N-Nitrosamine Contamination and Risk Assessment of N-Nitrosodimethylamine in Dried Aquatic Products
by: TANG Cuiying, CHEN Huafeng, HUANG Qishu, LI Jianwen, HUANG Siting CHEN Lijuan, FU Wusheng
Published: (2025-07-01)